CN106458969A - 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 - Google Patents

一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 Download PDF

Info

Publication number
CN106458969A
CN106458969A CN201580023470.2A CN201580023470A CN106458969A CN 106458969 A CN106458969 A CN 106458969A CN 201580023470 A CN201580023470 A CN 201580023470A CN 106458969 A CN106458969 A CN 106458969A
Authority
CN
China
Prior art keywords
alkyl
methyl
amino
alkoxy
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580023470.2A
Other languages
English (en)
Chinese (zh)
Inventor
魏用刚
李瑶
张国彪
邱关鹏
胡仕红
陈雷
李升�
张黔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN202110329149.4A priority Critical patent/CN113121575A/zh
Publication of CN106458969A publication Critical patent/CN106458969A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580023470.2A 2014-08-25 2015-08-25 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 Pending CN106458969A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110329149.4A CN113121575A (zh) 2014-08-25 2015-08-25 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410421609 2014-08-25
CN2014104216096 2014-08-25
CN2015100784973 2015-02-13
CN201510078497 2015-02-13
PCT/CN2015/088015 WO2016029839A1 (fr) 2014-08-25 2015-08-25 Dérivé aminé (subtitué phényle) (substitué pyrimidine), son procédé de préparation, et utilisation comme médicament

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110329149.4A Division CN113121575A (zh) 2014-08-25 2015-08-25 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途

Publications (1)

Publication Number Publication Date
CN106458969A true CN106458969A (zh) 2017-02-22

Family

ID=55398760

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110329149.4A Pending CN113121575A (zh) 2014-08-25 2015-08-25 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN201580023470.2A Pending CN106458969A (zh) 2014-08-25 2015-08-25 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110329149.4A Pending CN113121575A (zh) 2014-08-25 2015-08-25 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途

Country Status (2)

Country Link
CN (2) CN113121575A (fr)
WO (1) WO2016029839A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661000A (zh) * 2014-10-11 2017-05-10 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN110684016A (zh) * 2019-09-27 2020-01-14 上海应用技术大学 一种含氟的azd9291衍生物及其制备方法和应用
WO2024087419A1 (fr) * 2022-10-28 2024-05-02 浙大城市学院 Composé d'acide boronique hétérocyclique contenant de l'azote, son procédé de préparation et son utilisation

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
EP3229798A4 (fr) 2014-12-11 2018-05-30 Beta Pharma, Inc. Dérivés de 2-anilinopyrimidine substitués utilisés comme modulateurs de l'egfr
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
CN107344934B (zh) * 2016-05-04 2019-08-23 江苏正大丰海制药有限公司 药物活性物质的固体形式
JP6908287B2 (ja) * 2016-05-11 2021-07-21 ベータ ファーマ，インコーポレイテッド 脳腫瘍の処置のための治療剤としての２−アミノピリミジン誘導体
KR102444835B1 (ko) 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
EA201892661A1 (ru) * 2016-06-17 2019-07-31 Бета Фарма, Инк. Фармацевтические соли n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и их кристаллические формы
CN106432231B (zh) * 2016-09-09 2018-06-12 无锡佰翱得生物科学有限公司 Azd9291的药用盐、及其晶型和制备方法
JP6746794B2 (ja) * 2016-09-19 2020-08-26 南京創特医薬科技有限公司Ｎａｎｊｉｎｇ Ｃｈｕａｎｇｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ 重水素化３−（４，５−置換アミノピリミジン）フェニル誘導体及びその使用
CN107840846B (zh) * 2016-09-19 2020-11-24 郑州泰基鸿诺医药股份有限公司 一种含嘧啶环的化合物、egfr抑制剂及其应用
CN106674203A (zh) * 2016-11-25 2017-05-17 山东轩德医药科技有限公司 一种3‑(2‑氯嘧啶‑4‑基)‑1‑甲基吲哚的制备方法
KR102011356B1 (ko) * 2017-01-19 2019-08-16 부산대학교 산학협력단 신규한 2-아닐리노피리미딘 유도체 및 이를 포함하는 조성물
PT3514153T (pt) * 2017-01-26 2021-09-22 Hanmi Pharm Ind Co Ltd Composto de pirimidina e utilização farmacêutica do mesmo
US10633367B2 (en) * 2017-10-03 2020-04-28 X-Cutag Therapeutics, Inc. Fluorine- and/or deuterium-containing compounds for treating non-small cell lung cancer and related diseases
CN111825658A (zh) * 2019-04-18 2020-10-27 华东理工大学 新型egfr三突变抑制剂及其应用
TW202128670A (zh) * 2019-11-26 2021-08-01 大陸商上海翰森生物醫藥科技有限公司 含氮多環類衍生物抑制劑、其製備方法和應用
CN111303123B (zh) * 2020-03-31 2021-08-31 南京雷正医药科技有限公司 2-(2,4,5-取代苯胺基)嘧啶化合物及其应用
CN112159392B (zh) * 2020-09-15 2021-11-23 南京雷正医药科技有限公司 取代嘧啶化合物及其药物组合物和该化合物的用途
CN115867539A (zh) * 2020-12-02 2023-03-28 上海和誉生物医药科技有限公司 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用
AU2022323373A1 (en) * 2021-08-06 2024-01-18 Abbisko Therapeutics Co., Ltd. Pyrimidine or pyridine derivative, preparation method therefor, and application thereof in pharmacy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101902911A (zh) * 2007-10-19 2010-12-01 阿维拉制药公司 杂芳基化合物和其用途
CN102083800A (zh) * 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
CN103702990A (zh) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN104761585A (zh) * 2014-01-03 2015-07-08 南京波尔泰药业科技有限公司 作为egfr酪氨酸激酶的抑制剂的取代氨基嘧啶
CN104860941A (zh) * 2014-02-25 2015-08-26 上海海雁医药科技有限公司 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060565A1 (fr) * 2007-11-16 2009-05-20 4Sc Ag Nouveaux composés bifonctionnels inhibiteurs de protéine kinases et d'histone deacetylases
US8507502B2 (en) * 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
CN101503402B (zh) * 2009-03-10 2014-06-25 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
ES2715500T3 (es) * 2014-06-19 2019-06-04 Ariad Pharma Inc Compuestos de heteroarilo para la inhibición de la quinasa
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101902911A (zh) * 2007-10-19 2010-12-01 阿维拉制药公司 杂芳基化合物和其用途
CN102083800A (zh) * 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
CN103702990A (zh) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN104761585A (zh) * 2014-01-03 2015-07-08 南京波尔泰药业科技有限公司 作为egfr酪氨酸激酶的抑制剂的取代氨基嘧啶
CN104860941A (zh) * 2014-02-25 2015-08-26 上海海雁医药科技有限公司 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661000A (zh) * 2014-10-11 2017-05-10 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN106661000B (zh) * 2014-10-11 2019-04-09 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
US10259820B2 (en) * 2014-10-11 2019-04-16 Shanghai Hansoh Biomedical Co., Ltd. EGFR inhibitor, preparation method and use thereof
CN111170999A (zh) * 2014-10-11 2020-05-19 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN111171000A (zh) * 2014-10-11 2020-05-19 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN111187221A (zh) * 2014-10-11 2020-05-22 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN111170999B (zh) * 2014-10-11 2023-06-30 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN111171000B (zh) * 2014-10-11 2023-09-01 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN111187221B (zh) * 2014-10-11 2023-09-26 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN110684016A (zh) * 2019-09-27 2020-01-14 上海应用技术大学 一种含氟的azd9291衍生物及其制备方法和应用
WO2024087419A1 (fr) * 2022-10-28 2024-05-02 浙大城市学院 Composé d'acide boronique hétérocyclique contenant de l'azote, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
WO2016029839A1 (fr) 2016-03-03
CN113121575A (zh) 2021-07-16

Similar Documents

Publication Publication Date Title
CN106458969A (zh) 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
AU2019377130B2 (en) Fused ring compounds
TWI757256B (zh) 轉染過程重排之抑制劑
TWI618704B (zh) 作為ｅｇｆｒ調節劑之經取代之２－苯胺嘧啶衍生物
TWI715901B (zh) 作為ｆｇｆｒ抑制劑之雙環雜環
JP6510510B2 (ja) プロテインチロシンキナーゼモジュレーター及び使用方法
KR102564533B1 (ko) 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
TWI694078B (zh) 吡咯並三嗪類衍生物、其製備方法及其用途
US20110053931A1 (en) Quinoline compounds and methods of use
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
US20100256356A1 (en) Heterobicyclic pyrazole compounds and methods of use
CN105315285A (zh) 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
US20110130406A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
TWI555742B (zh) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, The use of medicine
PL216368B1 (pl) Związki aminoheteroarylowe oraz ich zastosowanie
CN109983016A (zh) 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
AU2014347126A1 (en) Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
JP7086272B2 (ja) イソインドリン－１－オン誘導体、同じものを調製する方法、およびがんを予防するまたは処置するための有効な構成要素として同じものを含む医薬組成物
CN108191837A (zh) PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
CN104250252B (zh) 吡唑并[1,5‑a]嘧啶类化合物及其制备方法和医药用途
CN108530428A (zh) 取代的嘧啶衍生物及其制备方法和药物用途
CN115677701A (zh) 一种苯并杂环化合物及其制备方法和应用
TW201605858A (zh) 縮合吡唑衍生物
CN105384695B (zh) 嘧啶衍生物及其制备方法和在医药上的应用
WO2023244430A1 (fr) Composés amide pyrimidine et leur utilisation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication